Fulgent Genetics (FLGT) Common Equity (2015 - 2026)

Fulgent Genetics has disclosed Common Equity across 12 years of filings, most recently posting $1.0 billion for Q2 2026.

• In Q2 2026, Common Equity fell 9.9% year-over-year to $1.0 billion; the TTM figure through Jun 2026 stood at $1.0 billion (down 9.9% YoY), while the FY2025 annual figure was $1.1 billion, down 1.52% from the prior year.
• Common Equity came in at $1.0 billion for Q2 2026 at Fulgent Genetics, down from $1.0 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $1.3 billion in Q1 2022 to a low of $1.0 billion in Q2 2026.
• Average Common Equity over 5 years is $1.2 billion, with a median of $1.1 billion recorded in 2023.
• Year-over-year, Common Equity jumped 63.8% in 2022 and declined 11.21% in 2024.
• Over 5 years, Common Equity stood at $1.3 billion in 2022, then decreased by 10.76% to $1.1 billion in 2023, then decreased by 0.36% to $1.1 billion in 2024, then retreated by 1.52% to $1.1 billion in 2025, then decreased by 9.93% to $1.0 billion in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $1.0 billion in Q2 2026, $1.0 billion in Q1 2026, and $1.1 billion in Q4 2025.